Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study

INTRODUCTION: Mitotane, the only drug approved by the Food and Drug Administration (FDA) for the treatment of adrenocortical carcinoma, is associated with several side effects including neurotoxicity. The aim of our study is to investigate the relationship between mitotane plasma levels and neurolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Mormando, Marilda, Galiè, Edvina, Bianchini, Marta, Lauretta, Rosa, Puliani, Giulia, Tanzilli, Antonio, Anceschi, Umberto, Simone, Giuseppe, Petreri, Gianluca, Graziano, Giuliana, Pace, Andrea, Appetecchia, Marialuisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461107/
https://www.ncbi.nlm.nih.gov/pubmed/37645432
http://dx.doi.org/10.3389/fonc.2023.1222002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461107/
https://www.ncbi.nlm.nih.gov/pubmed/37645432
http://dx.doi.org/10.3389/fonc.2023.1222002

Ejemplares similares